Incyte, Syndax Team Up On Chronic GVHD, But Some Uncertainties Remain

Data Still Early For Drug In $600m Deal

 
• By Alaric DeArment

The deal could nevertheless give Incyte a competitive edge, especially with combination potential between its JAK inhibitors and Syndax’s axatilimab.

Agreement business handshake partnership deal as a solution strategy with a team coming together out of tangled twisted roads on to a bridge to find a common goal.
Syndax and Incyte announced a deal worth more than $600m to develop drugs for chronic GVHD • Source: Shutterstock

More from Deals

More from Business